CAS: 5398-44-7; 2,6-Dichloroisonicotinic Acid

相似化合物

42521-09-5 32710-65-9 101990-69-6

上下游产品

CAS号99-11-6 2,6-二羟基异烟酸 | CAS号42521-09-5 甲基2,6二氯异烟 | CAS号98027-84-0 2,6-二氯-4-碘吡啶 | CAS号124-38-9 二氧化碳 | CAS号42521-08-4 2,6-二氯吡啶-4-羰酰氯 | CAS号824-72-6 苯膦酰二氯 | CAS号2402-78-0 2,6-二氯吡啶 | CAS号148493-37-2 2,6-二氯-3-碘吡啶 | CAS号84660-84-4 4-carboxy-2,6-d... | CAS号77-92-9 柠檬酸 | CAS号108994-42-9 2-氯-6-异丙氧基异烟酸 | CAS号586-95-8 4-吡啶甲醇 | CAS号498-94-2 4-哌啶甲酸 | CAS号501907-61-5 N-B°C-4-氨基-2,6-二氯吡啶 | CAS号42521-10-8 2-氯-6-甲氧基异烟酸甲酯 | CAS号183433-74-1 propyl 4-(1,2-d... | CAS号182483-63-2 2-苄氧基-6-氯-异烟酸 | CAS号183434-04-0 (S)-4-Ethyl-4,6... | CAS号194999-55-8 propyl (4S)-4-e... | CAS号86639-52-3 7-乙基-10羟基喜树碱

柠嗪酸置于四乙基氯化铵,三氯氧磷体系中,用71%的收率获得产物2,6-二氯异烟酸
参考文献:(S)-(-)-阿米巴酸的有效对映选择性合成.
标题:(S)-(-)-阿米巴酸的有效对映选择性合成.
摘要:[反应:请参见文本]使用(r,R)-[rh(dipamp)()通过脱氢氨基酸衍生物(3)的不对称氢化,实现了(S)-(-)-阿糖胞苷酸(1)的高效对映选择性合成. Cod)] Bf(4)催化剂,然后除去> 98%ee内的保护基,并在所有收率上均保持非常好.关键中间体(3)是由市售的瓜氨酸(4)分六步制备的.
DOI:10.1021/ol006363L

专利信息

专利号:US-6444820-B1
优先权日:1995-04-07
标题:Process for the manufacture of camptothecin derivatives
发明人：HENEGAR KEVIN E; SIH JOHN C
摘要:This invention discloses and claims novel intermediates and procedures for the synthesis of camptothecin derivatives, such as irinotecan, and other compounds related to the synthesis of CPT-11. Related procedures and compounds are also disclosed, such as a novel method of making mappicine.

专利号:US-2025304580-A1
优先权日:2021-11-09
标 题:Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
发明人：HOUZE JONATHAN B; PANDYA BHAUMIK; KAPLAN ALAN P; BOS MAXENCE; MANCUSO JOHN; FRANZONI IVAN
权利人:VIGIL NEUROSCIENCE INC
摘要:The present disclosure provides compounds of Formula I, useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 (“TREM2â€?).This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:US-8410028-B2
优先权日:2003-12-17
标 题:Methods for synthesis of encoded libraries
发明人：MORGAN BARRY; HALE STEPHEN; ARICO-MUENDEL CHRISTOPHER C; CLARK MATTHEW; WAGNER RICHARD; ISRAEL DAVID I; GEFTER MALCOLM L; BENJAMIN DENNIS; HANSEN NILS JAKOB VEST; KAVARANA MALCOLM J; CREASER STEFFAN PHILLIP; FRANKLIN GEORGE J; CENTRELLA PAOLO A; ACHARYA RAKSHA A
权利人:MORGAN BARRY; HALE STEPHEN; ARICO-MUENDEL CHRISTOPHER C; CLARK MATTHEW; WAGNER RICHARD; ISRAEL DAVID I; GEFTER MALCOLM L; BENJAMIN DENNIS; HANSEN NILS JAKOB VEST; KAVARANA MALCOLM J; CREASER STEFFAN PHILLIP; FRANKLIN GEORGE J; CENTRELLA PAOLO A; ACHARYA RAKSHA A; GLAXOSMITHKLINE LLC
摘要:The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag.

专利号:WO-2023091726-A1
优先权日:2021-11-18
标题:Inhibitors of cyclin‑dependent kinase 12 (cdk12)
发明人：BENOIT GUILLAUME; CARULLI JOHN; CHEN FEI; CHUAQUI CLAUDIO; CIBLAT STEPHANE; COOPER ELLIOT; DAGENAIS ROBIN; HU SHANHU; KABRO ANZHELIKA; LAPLACA DEREK; MARINEAU JASON; MOEBIUS DAVID; MOON DIANE; SOLODININ ANDREI; WHITMORE KENNETH
权利人:SYROS PHARMACEUTICALS INC
摘要:The present invention provides chemical compounds that inhibit one or more families of kinases (e.g., serine/threonine kinases, including one or more of the families of CDK proteins, and in particular, CDK12). More specifically, the present invention provides CDK12 inhibitors, of formula (I), pharmaceutically acceptable salts and isotopically labeled derivatives thereof, pharmaceutical compositions containing the compounds/inhibitors, and methods of their synthesis and use in treating proliferative diseases (e.g., a bladder cancer, a breast cancer, Ewing's sarcoma, a gastric cancer, a gastrointestinal cancer, a hematologic cancer, a lung cancer (e.g., small cell lung cancer (SCLC)), an ovarian cancer (e.g., a high grade serous ovarian cancer), a pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), a brain cancer (e.g., glioblastoma), or a prostate cancer), alone or in combination with a second therapeutic agent. The proliferative disease can be a cancer, benign neoplasm, or pathologic angiogenesis, and any of the therapeutic methods or uses described herein can include a step of diagnosing the patient's disease. In other embodiments of the invention, the compositions described herein (e.g., the compounds, pharmaceutical compositions, and kits containing them) are used for the treatment of myotonic dystrophy (type 1 or type 2).

专利号:US-2007042401-A1
优先权日:2003-12-17
标题 :Methods for synthesis of encoded libraries

专利号:US-2008058528-A1
优先权日:2006-07-20
标题 :Synthesis of (2S,5R)-5-ethynyl-1-{N-(4-methyl-1-(4-carboxy-pyridin-2-yl)piperidin-4-yl)glycyl}pyrrolidine-2-carbonitrile